Targeting the PPM1D phenotype; 2,4-bisarylthiazoles cause highly selective apoptosis in PPM1D amplified cell-lines
Matthew D Cheeseman1, Amir Faisal1, Sydonia Rayter1
1CRUK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, UK.
Abstract:
The metal-dependent phosphatase PPM1D (WIP1) is an important oncogene in cancer, with over-expression of the protein being associated with significantly worse clinical outcomes. In this communication we describe the discovery and optimization of novel 2,4-bisarylthiazoles that phenocopy the knockdown of PPM1D, without inhibiting its phosphatase activity. These compounds cause growth inhibition at nanomolar concentrations, induce apoptosis, activate p53 and display impressive cell-line selectivity. The results demonstrate the potential for targeting phenotypes in drug discovery when tackling challenging targets or unknown mechanisms.
Insights
Researchers discovered novel compounds that mimic the effects of reducing PPM1D (WIP1) oncogene levels in cancer cells. These drugs inhibit cancer growth and induce apoptosis, offering a new therapeutic strategy for challenging cancers.
Area of Science:
- Oncology
- Medicinal Chemistry
- Molecular Biology
Background:
- The PPM1D (WIP1) protein is a metal-dependent phosphatase implicated as an oncogene in various cancers.
- Overexpression of PPM1D correlates with poor clinical outcomes, highlighting its significance in cancer progression.
- Targeting PPM1D presents a therapeutic challenge due to its complex roles and potential for off-target effects.
Purpose of the Study:
- To discover and optimize novel compounds that phenocopy the effects of PPM1D knockdown.
- To identify agents that inhibit cancer cell growth and induce apoptosis without directly inhibiting PPM1D phosphatase activity.
- To explore a phenotype-based drug discovery approach for challenging oncogenic targets.
Main Methods:
- Synthesis and optimization of a novel series of 2,4-bisarylthiazole compounds.
- In vitro evaluation of compound efficacy, including growth inhibition assays and apoptosis induction.
- Assessment of compound effects on p53 activation and cell-line selectivity.
Main Results:
- Discovery of 2,4-bisarylthiazoles that effectively phenocopy PPM1D knockdown.
- Compounds demonstrated potent growth inhibition at nanomolar concentrations.
- Induction of apoptosis, activation of p53, and significant cell-line selectivity were observed.
- These compounds do not inhibit the phosphatase activity of PPM1D.
Conclusions:
- Novel 2,4-bisarylthiazoles represent a promising class of anti-cancer agents by phenocopying PPM1D knockdown.
- Phenotype-based drug discovery is a viable strategy for targeting challenging proteins like PPM1D.
- These findings offer a new avenue for developing therapies against cancers driven by PPM1D overexpression.
More Related Videos
15:53Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
Published on: August 21, 2013
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
